Hemodynamic, pharmacokinetic and clinical response to CI-930 in congestive heart failure due to ischemic or dilated cardiomyopathy

Keyphrases

• Active Metabolite 50%
• Blood Pressure 50%
• Cardiac Index 50%
• Clinical Response 100%
• Congestive Heart Failure 100%
• Dilated Cardiomyopathy 100%
• Duration of Action 50%
• Heart Blood 50%
• Heart Rate 50%
• Hemodynamic Effects 100%
• Hemodynamic Response 100%
• Hg(p) 50%
• Ischemic Cardiomyopathy 100%
• Oral Administration 100%
• Oral Dose 50%
• Peak Plasma Concentration 50%
• Pharmacokinetics 100%
• Phosphodiesterase Inhibitors 50%
• Plasma Concentration 50%
• Prolonged Duration 50%
• Pulmonary Capillary Wedge Pressure 50%
• Refractory Heart Failure 50%
• Systemic Vascular Resistance 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Active Metabolite 33%
• Congestive Cardiomyopathy 100%
• Congestive Heart Failure 100%
• Ischemic Cardiomyopathy 100%
• Oral Administration 66%
• Pharmacokinetics 100%
• Phosphodiesterase III Inhibitor 33%